Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolgolimab + chemo in 1L non-squamous NSCLC
NCT03912389Phase 3Unknown
- Sponsor
- BIOCAD
- Start
- Jun 2019
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing BCD-100 Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
prolgolimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03912389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03912389.